239 related articles for article (PubMed ID: 19458908)
1. Etanercept reduces the serum levels of macrophage chemotactic protein-1 in patients with rheumatoid arthritis.
Kageyama Y; Kobayashi H; Kato N; Shimazu M
Mod Rheumatol; 2009; 19(4):372-8. PubMed ID: 19458908
[TBL] [Abstract][Full Text] [Related]
2. Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3 alpha in patients with rheumatoid arthritis.
Kageyama Y; Ichikawa T; Nagafusa T; Torikai E; Shimazu M; Nagano A
Rheumatol Int; 2007 Dec; 28(2):137-43. PubMed ID: 17619881
[TBL] [Abstract][Full Text] [Related]
3. Serum chemokines in patients with rheumatoid arthritis treated with etanercept.
Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
Rheumatol Int; 2011 Apr; 31(4):457-61. PubMed ID: 20024555
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis.
Catrina AI; Lampa J; Ernestam S; af Klint E; Bratt J; Klareskog L; Ulfgren AK
Rheumatology (Oxford); 2002 May; 41(5):484-9. PubMed ID: 12011369
[TBL] [Abstract][Full Text] [Related]
5. Regulation of serum chemokines following infliximab therapy in patients with rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
Clin Exp Rheumatol; 2006; 24(5):529-33. PubMed ID: 17181921
[TBL] [Abstract][Full Text] [Related]
6. Etanercept treatment reduces the serum levels of interleukin-15 and interferon-gamma inducible protein-10 in patients with rheumatoid arthritis.
Ichikawa T; Kageyama Y; Kobayashi H; Kato N; Tsujimura K; Koide Y
Rheumatol Int; 2010 Apr; 30(6):725-30. PubMed ID: 20062995
[TBL] [Abstract][Full Text] [Related]
7. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
Catrina AI; Trollmo C; af Klint E; Engstrom M; Lampa J; Hermansson Y; Klareskog L; Ulfgren AK
Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
[TBL] [Abstract][Full Text] [Related]
8. Etanercept decreases synovial expression of tumour necrosis factor-α and lymphotoxin-α in rheumatoid arthritis.
Neregård P; Krishnamurthy A; Revu S; Engström M; af Klint E; Catrina AI
Scand J Rheumatol; 2014; 43(2):85-90. PubMed ID: 24313444
[TBL] [Abstract][Full Text] [Related]
9. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis.
Taylor PC; Peters AM; Paleolog E; Chapman PT; Elliott MJ; McCloskey R; Feldmann M; Maini RN
Arthritis Rheum; 2000 Jan; 43(1):38-47. PubMed ID: 10643698
[TBL] [Abstract][Full Text] [Related]
10. Involvement of IL-33 in the pathogenesis of rheumatoid arthritis: the effect of etanercept on the serum levels of IL-33.
Kageyama Y; Torikai E; Tsujimura K; Kobayashi M
Mod Rheumatol; 2012 Feb; 22(1):89-93. PubMed ID: 21674220
[TBL] [Abstract][Full Text] [Related]
11. Selective blockade of tumor necrosis factor receptor I inhibits proinflammatory cytokine and chemokine production in human rheumatoid arthritis synovial membrane cell cultures.
Schmidt EM; Davies M; Mistry P; Green P; Giddins G; Feldmann M; Stoop AA; Brennan FM
Arthritis Rheum; 2013 Sep; 65(9):2262-73. PubMed ID: 23784528
[TBL] [Abstract][Full Text] [Related]
12. Histological analysis of synovium by treatment of etanercept for rheumatoid arthritis.
Suzuki Y; Inoue K; Chiba J; Inoue Y; Kanbe K
Int J Rheum Dis; 2009 Apr; 12(1):7-13. PubMed ID: 20374310
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
[TBL] [Abstract][Full Text] [Related]
15. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
Park MC; Chung SJ; Park YB; Lee SK
Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450
[TBL] [Abstract][Full Text] [Related]
16. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT
Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966
[TBL] [Abstract][Full Text] [Related]
17. Histological patterns of synovitis and serum chemokines in patients with rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Latosiewicz R; Skowronski J; Cylwik JP; Cylwik B; Chwiecko J
J Rheumatol; 2005 Sep; 32(9):1666-72. PubMed ID: 16142858
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor-alpha increases chemokine gene expression and production in synovial fibroblasts from human temporomandibular joint.
Ogura N; Tobe M; Sakamaki H; Nagura H; Abiko Y; Kondoh T
J Oral Pathol Med; 2005 Jul; 34(6):357-63. PubMed ID: 15946184
[TBL] [Abstract][Full Text] [Related]
19. The effect of anti-tumor necrosis factor (TNF)-alpha therapy with etanercept on endothelial functions in patients with rheumatoid arthritis.
Tikiz H; Arslan O; Pirildar T; Tikiz C; Bayindir P
Anadolu Kardiyol Derg; 2010 Apr; 10(2):98-103. PubMed ID: 20382605
[TBL] [Abstract][Full Text] [Related]
20. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis.
Fabre S; Dupuy AM; Dossat N; Guisset C; Cohen JD; Cristol JP; Daures JP; Jorgensen C
Clin Exp Immunol; 2008 Aug; 153(2):188-95. PubMed ID: 18549443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
